Fundraising Fox
OraLiva
Durham, US · Founded 2019 · Delaware corporation · 14 employees on LinkedIn · 4 known investors
Find your way into OraLiva
Sign up to see every warm intro you have to OraLiva
- Paths you didn't know you had: your email and LinkedIn already hold routes to the OraLiva team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
OraLiva develops an AI-powered, non-invasive oral cancer test designed to detect cancer early during routine dental visits, using single-cell analysis and microfluidic technologies. The company is advancing a point-of-care diagnostic device for dental networks, building on its current lab-developed platform.
Also known as OraLiva, Inc.
Founders & leadership
OraLiva was founded in 2019 by John T. McDevitt.
Investors · 4
How we know: DCVC (Data Collective)'s portfolio page · the VCSheet dataset · research · oraliva.com · Not right? Tell us
Also in the syndicate · 2
Reported raises · per SEC filings
Form D private placements$1.5M disclosed across 1 of 2 rounds · 2025
▶$1.5MraisedMar 2025 · 1 investors · BiotechnologyRule 506(b)
- Anna GrassiniExecutive Officer, Director
- John McDevittDirector
- Offering amount
- $2.3M
- Amount sold
- $1.5M
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026OraLiva, Inc. is an AI precision diagnostics company that develops a non-invasive brush-biopsy test for oral cancer and dysplasia intended for use by dental providers. A soft brush collects transepithelial cells from a suspicious lesion during a routine exam, without scalpel or anesthesia; the sample is processed through the company's ONC In-Cyt platform, which combines a microfluidic cell-processing engine with deep-learning models trained on a dataset of more than 13 million cell images. Clinicians receive a digital report and a numerical risk score within days, supporting immediate patient counseling or referral to a specialist.
The company was founded out of the NYU School of Dentistry and the McDevitt Lab, and positions the product both as a currently available lab-developed test and as the basis for a regulated point-of-care device. Beyond oral cancer, OraLiva is applying transfer learning to extend its models to additional epithelial indications including anal, bladder and cervical cancers, funded in part by federal grants. Its stated roadmap covers expanding clinical partnerships, deepening AI capabilities, opening a CLIA-certified laboratory in Durham, North Carolina, and pursuing FDA clearance for point-of-care use.
Compiled by commissioned research from 10 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Founder mafia
2 people who came through OraLiva went on to found or lead other companies.
Timeline · 9
launches, deals, and filingsOraLiva, Inc. announced the close of a $2.0 million oversubscribed seed financing led by angel Dr. Preetpal Sidhu, with participation from DCVC, RTP Angel Fund and the NYU Innovation Venture Fund. CareQuest reporting notes the equity financing for the seed round was completed in early 2025.
$2M source ↗
Delta Dental of Michigan backs a four-state pilot program in Michigan, North Carolina, Ohio and Indiana with dentists, oral surgeons and periodontists, with year-two expansion planned to Arkansas, Kentucky, New Mexico and Tennessee.
NSF grant to add diagnostic capabilities for bladder and anal cancers and expand the platform to the point of care.
$1.2M source ↗
Direct to Phase II SBIR grant from the NIDCR Division of the NIH for Oral Lichenoid Lesions, to advance the oral cancer test toward point-of-care application.
$1.9M source ↗
NIH/NCI grant to extend the platform into gynecological services with point-of-care testing for cervical cancer.
$400K source ↗
Collaboration to expand clinical applications of the Orcellex device with OraLiva's oral cancer screening test.
Multi-phase pilot integrating AI-powered oral cancer screening into Enable Dental's mobile dental units serving seniors and adults with special needs; first phase covered clinical team training and provider materials, with dozens of adjunctive tests conducted later in 2025.
OraLiva was selected for CareQuest Innovation Partners' and MATTER's 2024 SMILE Health accelerator and was paired with Henry Schein as its industry partner.
Seed proceeds support commercial launch of the oral cancer test in Q4 2025 and the opening of a CLIA-certified laboratory in Durham, NC.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structureIn the news
▸Research sources · 10
primary sources listed
- OraLivaoraliva.com · web
10 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does OraLiva do?
- OraLiva is an AI cytology diagnostics company whose non-invasive brush biopsy test detects oral cancer and dysplasia chairside.
- Who founded OraLiva?
- OraLiva was founded by John T. McDevitt in 2019.
- Who are OraLiva's investors?
- OraLiva's investors include DCVC (Data Collective), NYU Innovation Venture Fund.
- How much funding has OraLiva raised?
- OraLiva has disclosed $1.5M raised across 1 of its 2 known rounds.
- Where is OraLiva headquartered?
- OraLiva is headquartered in Durham, US.